Literature DB >> 25574964

Effects of atorvastatin and pravastatin on immune activation and T-cell function in antiretroviral therapy-suppressed HIV-1-infected patients.

Edgar Turner Overton1, Sarah Sterrett1, Andrew O Westfall1, Shannon M Kahan2, Greer Burkholder1, Allan J Zajac2, Paul A Goepfert1,2, Anju Bansal1.   

Abstract

This retrospective study was designed to assess statin effects on T-cell activation from HIV-infected individuals. Peripheral blood mononuclear cells from antiretroviral therapy suppressed HIV-infected individuals receiving atorvastatin or pravastatin were evaluated for T-cell activation, exhaustion and function. Atorvastatin was associated with a significant reduction in CD8 T-cell activation (HLA-DR, CD38/HLA-DR) and exhaustion (TIM-3, TIM-3/PD-1) whereas pravastatin had no effect. In contrast, pravastatin increased antigen specific interferon γ production. These results suggest a differential effect of statins on immune activation and function.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25574964      PMCID： PMC4338916          DOI： 10.1097/QAD.0000000000000475

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  33 in total

1.  Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III).

Authors: 
Journal:  JAMA       Date:  2001-05-16       Impact factor: 56.272

2.  HIV infection induces age-related changes to monocytes and innate immune activation in young men that persist despite combination antiretroviral therapy.

Authors:  Anna C Hearps; Anna Maisa; Wan-Jung Cheng; Thomas A Angelovich; Gregor F Lichtfuss; Clovis S Palmer; Alan L Landay; Anthony Jaworowski; Suzanne M Crowe
Journal:  AIDS       Date:  2012-04-24       Impact factor: 4.177

3.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.

Authors:  Neil J Stone; Jennifer G Robinson; Alice H Lichtenstein; C Noel Bairey Merz; Conrad B Blum; Robert H Eckel; Anne C Goldberg; David Gordon; Daniel Levy; Donald M Lloyd-Jones; Patrick McBride; J Sanford Schwartz; Susan T Shero; Sidney C Smith; Karol Watson; Peter W F Wilson; Karen M Eddleman; Nicole M Jarrett; Ken LaBresh; Lev Nevo; Janusz Wnek; Jeffrey L Anderson; Jonathan L Halperin; Nancy M Albert; Biykem Bozkurt; Ralph G Brindis; Lesley H Curtis; David DeMets; Judith S Hochman; Richard J Kovacs; E Magnus Ohman; Susan J Pressler; Frank W Sellke; Win-Kuang Shen; Sidney C Smith; Gordon F Tomaselli
Journal:  Circulation       Date:  2013-11-12       Impact factor: 29.690

4.  Soluble CD163, a novel marker of activated macrophages, is elevated and associated with noncalcified coronary plaque in HIV-infected patients.

Authors:  Tricia H Burdo; Janet Lo; Suhny Abbara; Jeffrey Wei; Michelle E DeLelys; Fred Preffer; Eric S Rosenberg; Kenneth C Williams; Steven Grinspoon
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

5.  Immunologic failure despite suppressive antiretroviral therapy is related to activation and turnover of memory CD4 cells.

Authors:  Michael M Lederman; Leonard Calabrese; Nicholas T Funderburg; Brian Clagett; Kathy Medvik; Hector Bonilla; Barbara Gripshover; Robert A Salata; Alan Taege; Michelle Lisgaris; Grace A McComsey; Elizabeth Kirchner; Jane Baum; Carey Shive; Robert Asaad; Robert C Kalayjian; Scott F Sieg; Benigno Rodriguez
Journal:  J Infect Dis       Date:  2011-10-15       Impact factor: 5.226

6.  Immune activation in the pathogenesis of treated chronic HIV disease: a workshop summary.

Authors:  Susan F Plaeger; Brenda S Collins; Runa Musib; Steven G Deeks; Sarah Read; Alan Embry
Journal:  AIDS Res Hum Retroviruses       Date:  2011-09-27       Impact factor: 2.205

7.  Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death.

Authors:  E T Overton; D Kitch; C A Benson; P W Hunt; J H Stein; M Smurzynski; H J Ribaudo; P Tebas
Journal:  Clin Infect Dis       Date:  2013-02-05       Impact factor: 9.079

8.  Increased memory differentiation is associated with decreased polyfunctionality for HIV but not for cytomegalovirus-specific CD8+ T cells.

Authors:  Catherine Riou; Florette Treurnicht; Melissa-Rose Abrahams; Koleka Mlisana; Michael K P Liu; Nilu Goonetilleke; Richard Koup; Mario Roederer; Salim Abdool Karim; Guy de Bruyn; Carolyn Williamson; Clive M Gray; Wendy A Burgers
Journal:  J Immunol       Date:  2012-09-10       Impact factor: 5.422

9.  Programmed death-1 is a marker for abnormal distribution of naive/memory T cell subsets in HIV-1 infection.

Authors:  Gaëlle Breton; Nicolas Chomont; Hiroshi Takata; Rémi Fromentin; Jeffrey Ahlers; Abdelali Filali-Mouhim; Catherine Riou; Mohamed-Rachid Boulassel; Jean-Pierre Routy; Bader Yassine-Diab; Rafick-Pierre Sékaly
Journal:  J Immunol       Date:  2013-08-05       Impact factor: 5.422

10.  Tim-3 negatively regulates cytotoxicity in exhausted CD8+ T cells in HIV infection.

Authors:  Ali Sakhdari; Shariq Mujib; Bahareh Vali; Feng Yun Yue; Sonya MacParland; Kiera Clayton; Richard Bradley Jones; Jun Liu; Erika Yue Lee; Erika Benko; Colin Kovacs; Jennifer Gommerman; Rupert Kaul; Mario A Ostrowski
Journal:  PLoS One       Date:  2012-07-05       Impact factor: 3.240
View more
  13 in total

Review 1.  The Potential of the CNS as a Reservoir for HIV-1 Infection: Implications for HIV Eradication.

Authors:  Alessandro F Fois; Bruce J Brew
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

2.  Effects of pitavastatin and pravastatin on markers of immune activation and arterial inflammation in HIV.

Authors:  Mabel Toribio; Kathleen V Fitch; Laura Sanchez; Tricia H Burdo; Kenneth C Williams; Craig A Sponseller; Mary McCurdy Pate; Judith A Aberg; Markella V Zanni; Steven K Grinspoon
Journal:  AIDS       Date:  2017-03-27       Impact factor: 4.177

3.  Brief Report: No Evidence for an Association Between Statin Use and Lower Biomarkers of HIV Persistence or Immune Activation/Inflammation During Effective ART.

Authors:  Roger J Bedimo; Hanna Mar; Ronald J Bosch; Henning Drechsler; Joshua C Cyktor; Barnard J C Macatangay; Christina Lalama; Charles Rinaldo; Ann Collier; Catherine Godfrey; Evelyn Hogg; Christopher Hensel; Joseph J Eron; Deborah K Mcmahon; John W Mellors; Pablo Tebas; Rajesh T Gandhi
Journal:  J Acquir Immune Defic Syndr       Date:  2019-10-01       Impact factor: 3.731

Review 4.  Statins to improve cardiovascular outcomes in treated HIV infection.

Authors:  Chris T Longenecker; Allison R Eckard; Grace A McComsey
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

Review 5.  Immune activation and cardiovascular disease in chronic HIV infection.

Authors:  Chris T Longenecker; Claire Sullivan; Jason V Baker
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

6.  Statin exposure and risk of cancer in people with and without HIV infection.

Authors:  Roger J Bedimo; Lesley S Park; Fatima M Shebl; Keith Sigel; Christopher T Rentsch; Kristina Crothers; Maria C Rodriguez-Barradas; Matthew Bidwell Goetz; Adeel A Butt; Sheldon T Brown; Cynthia Gibert; Amy C Justice; Janet P Tate
Journal:  AIDS       Date:  2021-02-02       Impact factor: 4.632

7.  Atorvastatin downregulates co-inhibitory receptor expression by targeting Ras-activated mTOR signalling.

Authors:  Isobel Okoye; Afshin Namdar; Lai Xu; Nicole Crux; Shokrollah Elahi
Journal:  Oncotarget       Date:  2017-09-18

8.  Lovastatin Inhibits HIV-1-Induced MHC-I Downregulation by Targeting Nef-AP-1 Complex Formation: A New Strategy to Boost Immune Eradication of HIV-1 Infected Cells.

Authors:  Bingfeng Liu; Xu Zhang; Wanying Zhang; Liyang Wu; Shuliang Jing; Weiwei Liu; Baijin Xia; Fan Zou; Lijuan Lu; Xiancai Ma; Dalian He; Qifei Hu; Yiwen Zhang; Kai Deng; Weiping Cai; Xiaoping Tang; Tao Peng; Hui Zhang; Linghua Li
Journal:  Front Immunol       Date:  2019-09-10       Impact factor: 7.561

9.  Are statins beneficial for the treatment of SARS-CoV-2 infection?

Authors:  Auda Fares; Dieter Borrmann; Julius R Ivester
Journal:  J Infect Prev       Date:  2021-01-12

10.  Effects of Prednisolone on Disease Progression in Antiretroviral-Untreated HIV Infection: A 2-Year Randomized, Double-Blind Placebo-Controlled Clinical Trial.

Authors:  Christa Kasang; Samuel Kalluvya; Charles Majinge; Gilbert Kongola; Mathias Mlewa; Irene Massawe; Rogatus Kabyemera; Kinanga Magambo; Albrecht Ulmer; Hartwig Klinker; Eva Gschmack; Anne Horn; Eleni Koutsilieri; Wolfgang Preiser; Daniela Hofmann; Johannes Hain; Andreas Müller; Lars Dölken; Benedikt Weissbrich; Axel Rethwilm; August Stich; Carsten Scheller
Journal:  PLoS One       Date:  2016-01-26       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.